metformin zentiva 1000 mg tabletti, kalvopäällysteinen
zentiva, k.s. - metformin hydrochloride - tabletti, kalvopäällysteinen - 1000 mg - metformiini
metformin zentiva 850 mg tabletti, kalvopäällysteinen
zentiva, k.s. - metformin hydrochloride - tabletti, kalvopäällysteinen - 850 mg - metformiini
metformin zentiva 500 mg tabletti, kalvopäällysteinen
zentiva, k.s. - metformin hydrochloride - tabletti, kalvopäällysteinen - 500 mg - metformiini
sitagliptin/metformin reddy 50 mg / 1000 mg tabletti, kalvopäällysteinen
reddy holding gmbh - metformin hydrochloride, sitagliptin hydrochloride monohydrate - tabletti, kalvopäällysteinen - 50 mg / 1000 mg - metformiini ja sitagliptiini
sitagliptin/metformin reddy 50 mg / 850 mg tabletti, kalvopäällysteinen
reddy holding gmbh - metformin hydrochloride, sitagliptin hydrochloride monohydrate - tabletti, kalvopäällysteinen - 50 mg / 850 mg - metformiini ja sitagliptiini
vildagliptin / metformin hydrochloride accord
accord healthcare s.l.u. - metformin hydrochloride, vildagliptin - diabetes mellitus, tyyppi 2 - diabeetilla käytettävät lääkkeet - vildagliptin/metformin hydrochloride accord is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:- in patients who are inadequately controlled with metformin hydrochloride alone. - in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. - in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 ja 5. 1 käytettävissä olevista tiedoista eri yhdistelmistä).
vildagliptin/metformin stada 50 mg / 1000 mg tabletti, kalvopäällysteinen
stada arzneimittel ag - metformin hydrochloride, vildagliptin - tabletti, kalvopäällysteinen - 50 mg / 1000 mg - metformiini ja vildagliptiini
vildagliptin/metformin stada 50 mg / 850 mg tabletti, kalvopäällysteinen
stada arzneimittel ag - metformin hydrochloride, vildagliptin - tabletti, kalvopäällysteinen - 50 mg / 850 mg - metformiini ja vildagliptiini
icandra (previously vildagliptin / metformin hydrochloride novartis)
novartis europharm limited - vildagliptiini, metformiinihydrokloridia - diabetes mellitus, tyyppi 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - icandra is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 ja 5. 1 käytettävissä olevista tiedoista eri yhdistelmistä).
vildagliptin/metformin ratiopharm 50 mg / 850 mg tabletti, kalvopäällysteinen
teva b.v. - metformin hydrochloride, vildagliptin - tabletti, kalvopäällysteinen - 50 mg / 850 mg - metformiini ja vildagliptiini